

# Huiqun Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8667534/publications.pdf>

Version: 2024-02-01

21  
papers

197  
citations

1040056

9  
h-index

1125743

13  
g-index

21  
all docs

21  
docs citations

21  
times ranked

174  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. <i>Bioorganic Chemistry</i> , 2022, 120, 105641.	4.1	5
2	IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 191-202.	4.1	13
3	Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2761-2774.	4.1	3
4	Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators. <i>Future Medicinal Chemistry</i> , 2021, 13, 551-573.	2.3	4
5	Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5-epoxy-3,14-dihydroxy-6-[(4-pyridyl)carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. <i>Bioorganic Chemistry</i> , 2021, 109, 104702.	4.1	5
6	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7702-7723.	6.4	8
7	Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 127953.	2.2	2
8	Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2318-2324.	2.8	7
9	Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between <i>in Vitro</i> Agonist Bias and <i>in Vivo</i> Pharmacological Effects. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3036-3050.	3.5	17
10	Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors. <i>Future Medicinal Chemistry</i> , 2020, 12, 367-385.	2.3	3
11	Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators. <i>Journal of Computer-Aided Molecular Design</i> , 2020, 34, 879-895.	2.9	9
12	Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2518-2532.	3.5	17
13	Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11399-11415.	6.4	12
14	Structure-Activity Relationship Studies of $\mu$ - and $\delta$ -Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1075-1090.	3.5	28
15	Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(4-pyridyl)carboxamido]morphinan (NAP) Derivatives as $\mu/\delta$ Opioid Receptor Dual Selective Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 561-574.	6.4	17
16	Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2378-2392.	2.1	14
17	Understanding the role of glucose regulated protein 170 (GRP170) as a nucleotide exchange factor through molecular simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 160-170.	2.4	7
18	Methylation Products of $\delta$ -N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators. <i>ACS Chemical Neuroscience</i> , 2018, 9, 3028-3037.	3.5	6

#	ARTICLE	IF	CITATIONS
19	Exploring the binding mechanisms of diaminopimelic acid analogs to meso-diaminopimelate dehydrogenase by molecular modeling. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 83, 100-111.	2.4	3
20	Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2463-2471.	3.0	11
21	Diaminopimelic acid (DAP) analogs bearing isoxazoline moiety as selective inhibitors against meso-diaminopimelate dehydrogenase (m-Ddh) from <i>Porphyromonas gingivalis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3840-3844.	2.2	6